Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Jazz Pharmaceuticals, Servier Pharmaceuticals, LLC, and Takeda Oncology.
Medical Crossfire®: Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
Release Date: January 21, 2021
Expiration Date: January 21, 2022
Activity Overview
This online, on-demand continuing medical education (CME) activity brings together an international panel of experts on acute lymphoblastic leukemia (ALL) to exchange ideas and perspectives on the latest data regarding ALL management in adolescents and young adults (AYA), as well as older adults. Recent advances have been made in the diagnosis and management of ALL in these groups, including the development and incorporation of novel targeted and immune strategies and new assessments of measurable/minimal residual disease. The program features a case-based agenda allowing participants to consider how they might handle particular cases, integrate relevant evidence into real-world practice, and evaluate their current patient care approaches. This program will also address approaches to maximize the tolerability of current and emerging therapeutic approaches.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Jazz Pharmaceuticals, Servier Pharmaceuticals, LLC, and Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Utilize risk stratification strategies to develop appropriate treatment plans for adult as well as pediatric patients with ALL based on cytogenetic and immunophenotype characteristics
- Assess the importance of minimal residual disease and its role in determining prognosis as well as in treatment planning in adult and AYA patients with ALL
- Review the safety and efficacy of emerging therapies in the management of ALL, including monoclonal antibodies, antibody-drug conjugates, and CAR T-cell therapies
- Identify ALL patients who may benefit from clinical trial participation evaluating emerging ALL therapies and/or strategies
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: AbbVie, Adap-tive Biotechnologies, Amgen, Bristol Myers Squibb, Pfizer, Spec-trum Pharmateutical, Takeda
Head of Study Center
Depart of Medicine II, Hematology/Oncology
Goethe University Hospital
Frankfurt, Germany
Disclosures: Grant Research Support: Amgen, Incyte Corporation, Jazz Pharmaceuticals, Novartis, Pfizer, Servier Pharmaceuticals; Consultant: Amgen, Celgene, Erytech Pharma, Gilead, Incyte Corporation, Jazz Pharmaceuticals, Novartis, Pfizer
Professor and Chairman, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: No relevant financial relationships with commercial interests to disclose.
Member, St Jude Faculty
Chair, Oncology Department
Coleader, Hematological Malignancies Program
Director, China Region, St Jude Global
American Cancer Society Professor
Fahad Nassar Al-Rashid Chair of Leukemia Research
St Jude Children’s Research Hospital
Memphis, TN
Disclosures: Grant Research Support: NIH grant P30 CA021765; Speakers Bureau: Honoraria: Honoraria: Amgen, Erytech Pharma, Servier Pharmaceuticals
Clinical Lead, CAR-T
University College London Hospitals Senior Lecturer in Hematology
University College London NHS Foundation Trust
London, England
Disclosures: Speakers Bureau: Novartis, Gilead, Celgene
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.